Objective-Sympathetic nerve innervation of vascular smooth muscle cells (VSMCs) is a major regulator of arteriolar vasoconstriction, vascular resistance, and blood pressure. Importantly, α-adrenergic receptor stimulation, which uniquely couples with Panx1 (pannexin 1) channel-mediated ATP release in resistance arteries, also requires localization to membrane caveolae. Here, we test whether localization of Panx1 to Cav1 (caveolin-1) promotes channel function (stimulus-dependent ATP release and adrenergic vasoconstriction) and is important for blood pressure homeostasis. Approach and Results-We use in vitro VSMC culture models, ex vivo resistance arteries, and a novel inducible VSMC-specific Cav1 knockout mouse to probe interactions between Panx1 and Cav1. We report that Panx1 and Cav1 colocalized on the VSMC plasma membrane of resistance arteries near sympathetic nerves in an adrenergic stimulus-dependent manner. Genetic deletion of Cav1 significantly blunts adrenergic-stimulated ATP release and vasoconstriction, with no direct influence on endothelium-dependent vasodilation or cardiac function. A significant reduction in mean arterial pressure (total=4 mm Hg; night=7 mm Hg) occurred in mice deficient for VSMC Cav1. These animals were resistant to further blood pressure lowering using a Panx1 peptide inhibitor Px1IL2P, which targets an intracellular loop region necessary for channel function. composition of oligomeric coat-forming proteins called caveolins. 12 Of the 3 caveolin isoforms, Cav1 (caveolin-1) is essential for caveolae formation and function. [13] [14] [15] Cav1 has been shown to regulate vasoconstriction responses in small arterioles and to influence BP homeostasis in animal models. 13, [16] [17] [18] Importantly, Cav1 is expressed in VSMCs of small arteries and acts as a membrane-scaffold protein for both α-ARs and downstream G-protein-dependent vasoconstriction signaling molecules, 19, 20 suggestive of a role in adrenergic-mediated vasoconstriction.
I
n the peripheral circulatory system, blood pressure (BP) homeostasis is largely regulated by the contractile state of the vascular smooth muscle cells (VSMCs) in the wall of resistance arteries. Resistance arteries are small diameter (≤200 µm) arterioles that are composed of an intimal endothelial layer, a tunica media consisting of 1 to 2 VSMC layers, 1 and are functionally defined by the ability to respond to changes in intraluminal pressure to control vascular resistance and blood flow. Sympathetic nerve innervation of VSMCs is a major regulatory pathway that induces VSMC constriction, thus altering arteriolar lumen diameter and increasing the amount of vascular resistance. 2, 3 Although much is already known about the induction of rapid (purinergic) and potentiated (adrenergic) sympathetic nerve-derived stimuli on function of resistance arteries, 4 less is known about the identity of downstream VSMC signaling molecules that subsequently coordinate VSMC-derived stimuli in the arteriolar wall. Signaling through α-adrenergic receptors (α-ARs) and activation of plasma membrane-associated signaling molecules may be compartmentalized by caveolae near areas of sympathetic innervation. 2, [5] [6] [7] [8] Caveolae are specialized plasma membrane domains that play an important role in intracellular signaling, cellular transport, and differentiation. [9] [10] [11] Caveolae are defined by their hallmark plasma membrane morphology, consisting of 80-to 100-nm wide membrane invaginations, and by their composition of oligomeric coat-forming proteins called caveolins. 12 Of the 3 caveolin isoforms, Cav1 (caveolin-1) is essential for caveolae formation and function. [13] [14] [15] Cav1 has been shown to regulate vasoconstriction responses in small arterioles and to influence BP homeostasis in animal models. 13, [16] [17] [18] Importantly, Cav1 is expressed in VSMCs of small arteries and acts as a membrane-scaffold protein for both α-ARs and downstream G-protein-dependent vasoconstriction signaling molecules, 19, 20 suggestive of a role in adrenergic-mediated vasoconstriction.
Recently, our group and others [21] [22] [23] [24] have elucidated in mouse and humans an α-AR signaling axis that activates Panx1 (pannexin 1) channels. Pannexins are a family of transmembrane channel-forming glycoproteins that have emerged as the physiological conduit for controlled ATP release from vascular and nonvascular cell types. [25] [26] [27] We have previously reported that Panx1 expression is polarized within the vascular tree, with high expression levels in VSMCs of resistance arteries (eg, mesenteric, cremasteric, thoracodorsal, and coronary), but is not present in large conduit vessels, such as the femoral and carotid arteries, and the aorta. 28 This expression pattern suggests a unique role for Panx1 in regulating vascular resistance. Using Panx1 pharmacological inhibitors and inducible VSMC-specific Panx1 knockout mice, we have further demonstrated that Panx1-mediated ATP release and vasoconstriction are uniquely coupled with α-adrenergic stimulation and are crucial for maintaining BP homeostasis. 21, 22 Multiple groups have confirmed the activation of Panx1 channels by α-adrenergic stimulation, [29] [30] [31] thus demonstrating ATP release through Panx1 as a significant physiological pathway for integrating and coordinating VSMC-derived constriction responses. 4, 32 In the present study, we hypothesized that Cav1 acts as a molecular scaffold that concentrates VSMC Panx1 to areas important for sympathetic nerve innervation, thus supporting α-adrenergic vasoconstriction and BP homeostasis. In response to the α-adrenergic agonist phenylephrine, we observed a novel interaction and colocalization of Cav1 and Panx1 to regions of innervation at the VSMC plasma membrane. To investigate the functional role of Cav1 during α-adrenergic-mediated responses, we generated an inducible, VSMC-specific Cav1 knockout mouse model. We show that VSMC-derived Cav1 is required for α-adrenergic-stimulated ATP release and adrenergic vasoconstriction. Deletion of VSMC Cav1 results in a significant reduction in mean arterial BP, particularly during the nocturnal (active) period when sympathetic drive is high. Furthermore, we suggest that Cav1-mediated BP effects are regulated through the Panx1 intracellular loop regulatory domain, previously identified to be indispensable for α-adrenergic vasoconstriction. 22 
Methods

Data and Materials
All data will be made available on request by the corresponding authors at the University of Virginia.
Animals
All animals were cared for under the provisions of the University of Virginia Animal Care and Use Committee and the National Institute of Health guidelines for the care and use of laboratory animals. Male C57BL/6 mice between 10 and 15 weeks of age were purchased from Taconic. Male smooth muscle myosin heavy chain-Cre recombinase-modified estrogen receptor binding domain (SMMHC CreER   T2 )-modified mice, a kind gift from S. Offermanns, 33 were used for experimentation because of the restrictive presence of Cre recombinase on the Y chromosome. Aortae from connexin 43 globally deficient mice were harvested at birth. Mice harboring lox-P recombination sites for Cav1 (Caveolin-1 fl/fl ) were generated as previously described. 34 
Cell Culture
Primary human vascular coronary smooth muscle cells (VSMCs) were purchased from Lonza (Cat no. CC-2583). All cells were maintained under standard cell culture conditions (5% CO 2 at 37°C) in smooth muscle growth media (Lonza; Cat no. CC-3181) supplemented with smooth muscle growth factors (Lonza; Cat no. CC-3182) and 10% fetal bovine serum (Lonza; Cat no. CC-4102D). Cells were used at 8 passages or fewer for in vitro experiments. For all experiments, VSMCs were serum deprived for 48 hours in 0.2% fetal bovine serum to induce contractile phenotypes.
35-37
Ultrastructure Electron Microscopy
Mouse arteries were processed for ultrastructure transmission electron microscopy as previously described. 38 Images were obtained using a Joel 1230 transmission electron microscope at the Advanced Microscopy Core at the University of Virginia.
Proximity Ligation Assay (PLA) and Immunofluorescence
Thoracodorsal arteries (TDA) were isolated as previously described, 39 incubated in Krebs-HEPES physiological saline buffer, and treated with phenylephrine (20 µmol/L) in a single well of a 96-well dish. TDAs were then placed in a 1.5-mL Eppendorf tube, fixed in 4% paraformaldehyde, and subjected to en face PLA using the Duolink in situ PLA detection kit (Sigma) as previously described by us. 40 Sympathetic nerves were labeled using anti-mouse tyrosine hydroxylase antibody (Abcam no. ab112; 1:250 dilution) and visualized using an Alexa Fluor 568 secondary antibody (Life Technologies no. A-21099; 1:400 dilution 41 1:300 dilution). PLA detection was performed according to manufacturer's protocol. Immunofluorescence staining on aorta and TDAs was performed as previously described. 28 Primary antibodies for immunofluorescence included anti-rabbit connexin 43 antibody (Sigma no. C6219; 1:300 dilution) and vesicular nucleotide transport protein (anti-mouse vesicular nucleotide transporter; a kind gift from Dr Chen Li, 1:200 dilution). All images were acquired using an Olympus Fluoview 1000 confocal microscope. PLA punctate spots were counted per 100 μm2 cell area. Cav1 deletion was quantified using batch-processed tissue and threshold generated images. The relative fluorescence intensity within the smooth muscle cell layer (demarcated by coassociation with smooth muscle actin [Acta2] staining, and between the boundary lines of the internal elastic lamina and adipose tissue) was measured using ImageJ 42 and normalized to Acta2-positive area. Co-staining for smooth muscle cells (Acta2; Sigma no. A2547, 1:500 dilution) and CD31-positive endothelial cells (PECAM-1 [platelet endothelial cell adhesion molecule-1]; Santa Cruz no. sc28188, 1:400 dilution) was performed. Data are presented as mean±SEM. A Student t test was performed for statistical significance (*P<0.05).
Live Cell Imaging
Confocal imaging was performed with a Leica TCS SP8 confocal microscope. Human VSMCs were cultured as indicated above and plated on 100 μg/mL poly-d-lysine on cover glass. Cells were transfected with plasmids encoding Panx1-RFP (red fluorescent protein) 43 and Cav1-GFP (green fluorescent protein) using jetPRIME (polyplus transfection/ VWR) according to the manufacturer's protocol. Image acquisition and codistribution analyses were performed double-blinded to treatment conditions with identical imaging parameters. For live imaging, baseline images were collected at 30-second intervals for 2 minutes using a ×20 (0.7 numerical aperture) objective. Importantly, the large cellular size (range of lengths) permitted imaging of only 1 cell per field of view. Treatment with phenylephrine (100 μmol/L; Sigma-Aldrich), ATP (500 μmol/L; Sigma-Aldrich), or vehicle control (water) was performed by removing half the volume of control media and replacing it with the same volume of media containing 2× agonist. Images were collected at 30-second intervals up to 5 minutes. The z-section containing the largest cellular area was selected for Mander coefficient analysis of Panx1-Cav1 codistribution using the JACoP plugin in FIJI. 44 All post-treatment data were normalized to the average obtained at baseline. Data were collected from n=5 to 11 cells per experimental condition and analyzed using a 2-way ANOVA for time and treatment (time: F [10, 250] 
Membrane Fractionation and Isolation of Cav1-Enriched Membrane Domains
Human VSMCs were grown to confluence and incubated in media containing 0.2% fetal bovine serum for 48 hours before use. VSMCs were washed with PBS and re-equilibrated for 10 minutes in Krebs buffer (mmol/L: 118.4 NaCl, 4.7 KCl, 1.2 MgSO 4 , 4 NaHCO 3 , 1.2 KH 2 PO 4 , 10 HEPES, 6 glucose) containing 2 mmol/L CaCl 2 . VSMCs were treated with 100 µmol/L phenylephrine or vehicle control, scraped with a cell scraper, and lysed in ice-cold detergent-free lysis buffer (500 mmol/L Na 2 CO 3 , 50 mmol/L NaF, 2 mmol/L Na 3 VO 4 , pH 11, supplemented with 1 mg/mL of protease inhibitor cocktail [Sigma] , and 1 mg/ mL P2 and P3 phosphatase inhibitor cocktails [Sigma] ). Lysates were homogenized using a dounce homogenizer (10 strokes) and sonication (25 pulses for 1 second) on ice. Lysates were either fractioned using differential centrifugation (40 000 rpm; 1 hour Beckman XL80 ultracentrifuge with Sw55Ti rotor) or using centrifugation across a sucrose gradient. To create a sucrose gradient, sucrose solutions were mixed in modified Barth's saline-sodium carbonate buffer (25 mmol/L MES [2-(N-morpholino)ethanesulfonic acid], 0.5 mol/L NaCl, 250 mmol/L Na 2 CO 3 ) to 85%, 30%, and 5% by mass by adding 42.5, 15, or 2.5 g of sucrose, respectively, to 50 mL of modified Barth's saline. Lysates were mixed with equal volume of 85% sucrose solution to create 42.5% layer. A total of 1.5 mL of 42.5% layer was added to the bottom of a Sw55Ti ultracentrifuge tube, after which a 5% to 42.5% discontinuous sucrose gradient was formed by adding, dropwise on top of previous layers, 1 mL of 30% sucrose solution followed by 1 mL of 5% sucrose solution. Gradients were centrifuged at 42 000 rpm for 18 hours in a Beckman XL80 ultracentrifuge with Sw55Ti rotor. Ten fractions of 350 μL each were removed starting from the top of the gradient and analyzed using Western blot with antibodies for rabbit anti-human Panx1 (characterized by Penuela et al 45 1:1000 dilution) and mouse anti-Cav1 (BD Biosciences no. 610406; 1:1000 dilution). Coimmunoprecipitation was performed using either Panx1 antibodies (1:50 dilution) in conjunction with anti-rabbit IgG Dynabeads (Invitrogen), respectively. To perform coimmunoprecipitations, Cav1-enriched fractions (4-5) and nonenriched fractions (7) (8) were combined, and total protein from each was measured by bicinchoninic acid assay. Equal amounts of protein from each pair of fractions was used for coimmunoprecipitation as described above. Five independent experiments were performed. The ratio of Cav1 signal was normalized to the amount of immunoprecipitated Panx1. Data are represented as mean±SEM. A Student t test was performed for statistical significance (*P<0.05).
Western Blot
After stimulation with adrenergic agonists, human VSMCs were homogenized in ice-cold NP-40 extraction buffer (50 mmol/L Tris-HCL, 150 mmol/L NaCl, 5 mmol/L EDTA, 1% deoxycholate, 1% NP-40, and 1% Triton-X100 in PBS and pH adjusted to 7.4) containing protease inhibitor cocktail (Sigma) and P2/P3 phosphatase inhibitor cocktail (Sigma). Cell/tissue lysates were incubated at 4°C for 10 minutes to solubilize proteins, sonicated for 12 pulses for 1 second each, and centrifuged for 10 minutes at 12 000 rpm to pellet cell debris. Protein concentration was determined using the bicinchoninic acid assay method (Pierce). Ten to 20 µg of total protein was loaded into each sample well. Samples were subjected to SDS gel electrophoresis using 4% to 12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membrane for immunoblotting. Membranes were blocked for 1 hour at room temperature in a solution containing 3% BSA in Tris buffered saline and then incubated overnight at 4°C with primary antibodies against rabbit anti-Panx1 (Cell Signaling Technology no. 91137 [D9M1C]; 1:1000 dilution), rabbit anti-Cav1 (BD Biosciences no. 610059; 1:1000 dilution), rabbit anti-transferrin receptor (Abcam no. ab84036; 1:1000 dilution), and mouse anti-GAPDH (Sigma mAb no. G8795; 1:10 000). Membranes were washed and incubated in LiCOR IR Dye secondary antibodies (1:15 000) for 1 hour and viewed/quantified using the LiCOR Odyssey with Image Studio software. Representative Western blot images have been cropped for presentation.
Pressure Myography
Pressure myography was performed on TDAs as previously described. 39 Briefly, mice were euthanized using CO 2 asphyxia. TDAs were microdissected, cannulated on glass pipettes in a temperaturecontrolled pressure arteriography chamber, and pressurized to 80 mm Hg. After a 30-minute equilibration period in Krebs-HEPES with 2 mmol/L Ca 2+ , vessels were treated with cumulative doses of phenylephrine (10 −10 -10 −3 mol/L) applied to the bath. The luminal diameter was analyzed using digital calipers in the Danish Myo Technology vessel acquisition software (Danish Myo Technology). Smooth muscle cell viability was assessed using serotonin (1 μmol/L) and KCl (30 mmol/L). Endothelial-dependent vasodilation was measured using cumulative doses of acetylcholine (10 −11 -10 −2 mol/L) as previously described. 39 A 2-way ANOVA with Bonferonni post hoc test was performed for multiple comparisons. Concentration-effect curves were fitted to the data using 4-parameter, nonlinear regression curve fitting using GraphPad (version 7).
ATP Measurements
For the measurement of extracellular ATP, intact TDAs of equal length were placed in individual wells of a 96-well plate in Krebs-Hepes physiological solution for 15 minutes. The ectonucleotidase inhibitor ARL 67 156 trisodium (Tocris; 100 µmol/L) was added 30 minutes before treatment with contractile agonists as previously described. 22 Vasoconstrictor compounds were added to the incubation media for 5 minutes to allow ATP accumulation: phenylephrine (20 µmol/L), norepinephrine (20 µmol/L), serotonin (5-HT [5-hydroxytryptamine] ; 40 nmol/L), and endothelin-1 (40 nmol/L; all purchased from Sigma). After stimulation, the media surrounding the vessel was collected and immediately placed into prechilled 1.5 mL Eppendorf tubes on ice. All samples were centrifuged at 10 000g for 5 minutes. For intracellular ATP measurements, TDAs were microdissected, cleaned of adventitia, and cut into equal 10.5 mm vessel segments. Segments were individually lysed in ATP lysis buffer according to manufacturer's protocol, spun at 10 000g for 1 minute, and samples collected. ATP concentration in the incubation media was quantified using the ATP bioluminescence assay kit HSII (Roche) using a FluoStar Omega plate reader luminometer. Extracellular ATP measurements for each sample were tested in triplicate and calculated using an ATP standard curve for all experiments. Intracellular ATP measurements were measured from 3 vessel segments (1 TDA in triplicate). Data are presented as % change in ATP release from baseline (unstimulated) or as the concentration of ATP in the media compared with control samples. One-way ANOVA with Tukey test was performed for statistical significance of extracellular ATP. A Kruskal-Wallis (1-way ANOVA on ranks) with Dunn post hoc test performed for intracellular ATP. Significance denoted as *P<0.05.
BP Telemetry
BP was measured using telemetry equipment as previously described. 22 Briefly, telemeters (Data Sciences International) were implanted in C57BL/6 or SMMHC-CreER
fl/fl (SMC-Cav1 fl/fl ) mice. Under isoflurane anesthesia, the catheter of a single telemetry unit (TA11PA-C10, Data Sciences International) was implanted in the left carotid artery and the transmitter placed in a subcutaneous pouch along the right flank of the mouse. After implantation surgery, mice were allowed to recover for 7 days to re-establish normal circadian rhythms and BP. For experiments using inducible Cre recombinase, mouse BP baselines were continuously recorded using Dataquest A.R.T. 20 software (Data Sciences International) for 5 days after normal recovery and before starting intraperitoneal tamoxifen injections or vehicle control (peanut oil) for 10 days. BP was recorded for an additional 5 days starting 24 hours after the last tamoxifen injection. Change in mean arterial pressure (∆MAP) was calculated by subtracting the average MAP measured before tamoxifen injections to the MAP after tamoxifen injections. Diurnal (inactive period) MAP was measured during animal's light cycle: 6:00 am to 5:59 pm, and nocturnal (active period) MAP was measured during the animal's dark cycle: 6:00 pm to 5:59 am MAPs before and after tamoxifen injections were compared with a Wilcoxon test (nonparametric paired t test). C57BL/6 mice similarly received intraperitoneal injections of tamoxifen or vehicle control, and basal BP was measured as for transgenic animals. For assessment of the BP effects of the Px1IL2P peptide inhibitor (formerly referred to as Px1IL2P peptide 22 ), animals were intraperitoneally injected with saline vehicle control or peptide (20 mg/kg in a volume not exceeding 100 µL). BP was recorded for 2 hours after injection, and the MAP data were averaged and compared with the basal BP. ∆MAP was calculated by subtracting the baseline MAP 30 minutes before injection from the MAP measured during the final 30 minutes of the 2-hour treatment period. Data represent mean±SEM. Two-way ANOVA with Tukey post hoc test was performed for assessment of MAP before and after tamoxifen/vehicle control induction and for mice treated with scrambled peptide or PxIL2P peptide inhibitor.
Cardiac Magnetic Resonance Imaging (MRI) and Histology
All MRI animal studies were performed under protocols that comply with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, Revised 1996) and were approved by the Animal Care and Use Committee at our institution (University of Virginia). Mice were positioned supine in the scanner, and body temperature was maintained at 36°C±0.5°C using thermostatic circulating water. Anesthesia used was 1.25% isoflurane in O 2 inhaled through a nose cone during imaging. A 30-mm diameter cylindrical birdcage relative fluorescence coil (Bruker) with an active length of 70 mm was used, and heart rate, respiration, and temperature were monitored during imaging using a fiber optic, MR-compatible system (Small Animal Imaging Inc, Stony Brook, NY). MRI was performed on a 7 Tesla (T) Clinscan system (Bruker, Ettlingen, Germany) equipped with actively shielded gradients with a full strength of 650 mT/m and a slew rate of 6666 mT/m per millisecond. Baseline left ventricle structure and function were assessed. 46 Six short-axis slices were acquired from base to apex, with slice thickness equal to 1 mm, in-plane spatial resolution of 0.2×0.2° mm 2 , and temporal resolution of 8 to 12 ms. Baseline ejection fraction, enddiastolic volume, end-systolic volume , myocardial mass, wall thickness, and wall thickening were measured from the cine images using the freely available software Segment version 2.0 R5292 (http:// segment.heiberg.se). End-diastolic volume and end-systolic volume were then indexed to body mass. Mass to volume ratiowas calculated as the ratio of myocardial mass to end-diastolic volume.
Plasma Renin ELISA
Mice were anesthetized using 2,2-Dicholor-1,1-difluoroethyl methyl ether (ThermoFisher; no. 76-38-0). One hundred to 150 μL of whole blood was collected from mouse tail veins using heparinized capillary tubes into 1.5mL Eppendorf, stored on ice, and centrifuged for 15 minutes at 1000 rpm. Plasma was aliquoted, snap frozen, and stored at −80°C. Plasma renin concentration was measured using a total renin ELISA (RayBio; no. ELM-Ren1) against a renin standard curve with 1:15 dilution of samples. Student t test (2 tailed) was performed for significance.
Statistics
All data were analyzed using GraphPad Prism v5.0 for live cell image analysis or v7.0 software for all other analyses. Briefly, D'AgostinoPearson tests were used to determine normality. Brown-Forsthe/ Barlett tests were used to determine equal variance for ANOVA, and F-test was used to determine equal variance for t test in GraphPad Prism v7.0 software. Data that passed normality tests and equal variance tests were analyzed by t test for 2 groups or ANOVA for ≥3 groups. Data that were not normally distributed were analyzed by Kruskal-Wallis test (≥3 groups). Post hoc analysis for multiple comparisons were selected as appropriate to test for statistical significance (*P<0.05, **P<0.01, ***P<0.001). Results are presented as mean±SEM.
Results
Caveolae are specialized plasma membrane domains that facilitate interactions between signaling proteins (ie, Gq [G-protein alpha subunit], PLC [phospholpase C], Src [Src kinase], etc 12, 47, 48 ) and membrane receptors (ie, α-ARs
48
). These structures are found in endothelium and smooth muscle; however, their signaling functions are much less studied in smooth muscle. In electron micrographs, we consistently observe caveolae contained in arteriolar smooth muscle in proximity to sympathetic nerves ( Figure I in the online-only Data Supplement). For this reason, we hypothesized that the Cav1 protein, the main component to caveolae, may associate with Panx1, which is activated in response to adrenergic stimulation.
In initial experiments, we performed live-cell confocal microscopy using in vitro human VSMC culture systems to measure the distribution and colocalization of exogenously expressed RFP-tagged Panx1 and GFP-tagged Cav1 after phenylephrine stimulation ( Figure 1A ). Baseline fluorescence measurements were recorded for 2 minutes before stimulation with phenylephrine (100 µmol/L), vehicle control, or high concentration ATP (500 µmol/L) to promote Panx1 internalization. A strong and significant codistribution was observed between Cav1 and Panx1 at 30 seconds of phenylephrine stimulation at the plasma membrane ( Figure 1A and 1B), which persisted above control fluorescence, although not to statistically significant levels ( Figure 1B and 1C) . Conversely, treatment with high-concentration ATP caused a significant and continuous reduction in colocalized signal, consistent with internalization and loss of Panx1 on the cell surface 49, 50 that is independent of Cav1-mediated endocytosis. 43 Vehicle control-treated cells showed no changes in fluorescence colocalization from baseline.
To confirm observations from live-cell imaging experiments, we next performed in vitro cell fractionation and coimmunoprecipitation assays using in vitro VSMC culture systems to probe for endogenous interactions between Panx1 and Cav1 at the plasma membrane. We found that Cav1 and Panx1 localize to membrane-associated fractions ( Figure 1D ) and specifically overlap in Cav1-enriched sucrose-gradient fractions, suggesting partial localization of Panx1 to lipid microdomains containing Cav1 ( Figure 1E ). To determine whether Cav1 and Panx1 interact after adrenergic stimulation, we acutely treated VSMCs with phenylephrine (20 µmol/L). Fractions enriched or deficient in Cav1 were isolated, and Panx1 was precipitated using a protein specific antibody. 45 We found that Cav1 from enriched fractions significantly coprecipitated with Panx1 after adrenergic stimulation ( Figure 1F ), suggesting that plasma membrane complexes containing Cav1 and Panx1 form after adrenergic stimulation and may act to facilitate channel function.
Panx1-mediated ATP release and subsequent vasoconstriction are specifically mediated through α-AR activation. 21, 22, [29] [30] [31] Based on our initial observations and the in vitro biochemical findings herein ( Figure 1F ), we first tested whether Cav1 and Panx1 similarly interact in VSMCs of ex vivo isolated mouse resistance arteries. We performed PLA between Panx1 and Cav1 on TDAs and assessed the focal plane where sympathetic nerves innervate VSMC ( Figure  II in the online-only Data Supplement). Sympathetic nerves were specifically labeled with tyrosine hydroxylase. In control experiments using PLA secondary antibodies alone or IgG controls, we could not detect PLA punctate signals (red puncta indicate protein associations when PLA probes <40 nm in apposition)-only sympathetic nerves could be viewed (Figure 2A and 2B) . Next, we performed PLA for Cav1 and Panx1. Here, we observed relatively few positive red punctate signals under control conditions ( Figure 2C) ; however, after acute (1 minute) phenylephrine stimulation (20 μmol/L), we observed an induction of PLA signal, which predominantly localized at the VSMC plasma membrane near areas of sympathetic nerve innervation ( Figure 2D-2E) . As a control, TDA smooth muscle and sympathetic nerves were also analyzed for connexin 43 expression, but it was not detected ( Figure ; Figure 3A and 3B). Cav1 deletion was specific for VSMCs of resistance arteries and not affecting Cav1 expression in CD31-positive endothelial cells (Figure 3C and 3D) . Because of the well-established contribution of Panx1-mediated ATP release during adrenergic stimulation, 21, 22, 29, 51 we measured vasoconstrictor-dependent ATP release from isolated resistance arteries. Using a luminescence-based assay, we observed a Cav1-dependent response, whereby ATP released after adrenergic stimulation (norepinephrine 20 μmol/L or phenylephrine 20 μmol/L) was significantly reduced in SMC-Cav1 Δ/Δ mice compared with controls ( Figure 3E ). No significant effect on ATP release was observed in any of the genotypes tested in response to agonists for other potent vasoconstriction pathways (eg, endothelin-1 or 5-HT; Figure 3E ). Intracellular ATP concentration was also unchanged in any of the genotypes tested ( Figure IV in the online-only Data Supplement).
In line with our ATP findings, we reasoned that blunted adrenergic-mediated ATP release in SMC-Cav1 Δ/Δ mice would concomitantly impair vascular responses to phenylephrine. To directly measure vasoconstriction responses in ex vivo resistance arteries, we assessed vascular responses to increasing concentrations of phenylephrine using pressure myography.
SMC-Cav1
Δ/Δ mice exhibited significant reductions in phenylephrine-stimulated vasoconstriction (red line) compared with control animals (black line; Figure 4A ). Unlike global Cav1 knockout mice, which exhibit reduced expression of endothelial cell Cav1, 16, 52 no significant differences were observed in endothelium-dependent vasodilation (acetylcholine responses) in SMC-Cav1 Δ/Δ mice ( Figure 4B ). Thus, VSMCspecific deletion of Cav1 impairs adrenergic vasoconstriction without altering endothelial-mediated responses.
Previously, we have shown that VSMC-specific deletion of Panx1 channels results in significantly reduced BP because of blunted adrenergic-stimulated ATP release and vasoconstriction. Thus, we used telemetry to test whether SMC-Cav1 Δ/Δ mice exhibited a similar BP phenotype. BP was assessed in individual animals before (baseline) and after induction of Cav1 deletion. A significant reduction in 24-hour MAP (total MAP=−3.8 mm Hg) was observed only after tamoxifen injection in SMC-Cav1 Δ/Δ mice ( Figure 5A and 5B). Moreover, a significant and greater BP reduction (∆MAP=−6.8 mm Hg) was observed during the active period when sympathetic drive to resistance arteries is higher ( Figure 5C ) compared with the inactive period ( Figure 5D ). No significant difference in baseline MAP was observed in any other tested genotype before induction with tamoxifen, vehicle control, or saline control ( Figure 5C ; Figure V in the online-only Data Supplement). There was also no change in plasma renin concentration after To ensure that BP reductions in SMC-Cav1 Δ/Δ mice were not influenced by changes in cardiac function, we performed functional MRI analysis on SMC-Cav1 Δ/Δ and control animals ( Figure 6 ). No significant changes in cardiac function were observed in any of the tested genotypes (Table) . This includes cardiovascular changes because of heart rate, stroke volume, cardiac output, left ventricular mass, or left ventricular wall thickness-all of which can directly influence MAP. Lastly, mice lacking the Cre allele, but maintaining the loxP genotype and injected with tamoxifen, showed no changes in expression of Cav1 in arteries, phenylephrine dose-responses, or MRIs ( Figure VI in the online-only Data Supplement; Table I in the online-only Data Supplement).
To functionally assess whether BP reductions involving VSMC Cav1 are mediated through a Panx1-dependent pathway, we acutely treated animals with the Panx1 intracellular loop mimetic peptide inhibitor PxIL2P (20 mg/kg) or scrambled control peptide (20 mg/kg). We have previously shown that PxIL2P significantly blunts phenylephrine-stimulated Panx1 channel currents, ATP release, vasoconstriction, and MAP. 22 After acute injection of PxIL2P, significant BP reduction was restricted to vehicle-treated SMC-Cav1 fl/fl (vehicle treated: ∆MAP=−8.83 mm Hg) and C57BL/6 (vehicle treated: ∆MAP=−12.26 mm Hg; tamoxifen: ∆MAP=−9.81 mm Hg) control animals-both of which contain VSMC Cav1. Conversely, no significant changes in MAP were observed in SMC-Cav1 ∆/∆ animals, which are deficient in VSMC Cav1 (tamoxifen: ∆MAP=0.73 mm Hg; Figure 7 ). Administration of a scrambled PxIL2P peptide of the same amino acid composition did not influence BP in any genotype tested. The resistance of VSMC-specific Cav1-deficient mice to BP lowering by PxIL2P supports the idea that VSMC caveiolin-1 regulates BP homeostasis through changes in Panx1 localization and channel function.
Discussion
Sympathetic-mediated vasoconstriction plays a central role in controlling BP homeostasis. This process occurs, in part, because of the release of norepinephrine from sympathetic nerves, subsequent activation of VSMC α-ARs, and coordinated constriction between VSMCs, thus producing a unified vasoconstriction response. Recent work from our group revealed that VSMC Panx1 channels 21 are a primary mediator of α-AR vasoconstriction, and using VSMC-specific Panx1 knockout mice and genetic rescue experiments, we demonstrated that ATP release from these channels was necessary for proper adrenergic vasoconstriction. 21, 53 In this way, ATP acts as an autocrine/paracrine signaling molecule that initiates vasoconstriction responses in resistance arteries. However, less is known about the intracellular signaling molecules responsible for supporting Panx1 channel function after adrenergic stimulation. Here, we have identified a novel interaction between Panx1 and the caveolae structural protein Cav1. Cav1 and Panx1 localize to areas of the plasma membrane innervated by sympathetic nerves and associate with each other after stimulation of α-ARs with phenylephrine. Using a novel, inducible, VSMC-specific Cav1 knockout mouse, we also demonstrate that Cav1 functionally regulates adrenergic-mediated ATP release, vasoconstriction, MAP, and Panx1-dependent BP responses.
Plasma membrane caveolae influence vascular homeostasis and assist in the localization of key VSMC vasoconstriction signaling molecules, such as α-AR and Gq-coupled effector molecules in small arteries. 19, 48, 54 From electron microscopy observations ( Figure I in the online-only Data Supplement), we often observe caveolae localized near sympathetic nerves, and thus predicted that this unique vascular feature may beget vascular function. Our live cell, fluorescent tracking experiments, allowed us to examine Cav1 and Panx1 interactions in response to stimulation with phenylephrine. Activation of α-AR resulted in a rapid coassociation of the 2 proteins at the plasma membrane ( Figure 1A and 1B) . These temporal effects are consistent with previous constriction recordings after adrenergic stimulation in resistance arteries. 8, 55 Moreover, we treated VSMCs with a high concentration of ATP (500 µmol/L), a manipulation that promotes active internalization of membrane-associated Panx1, 49 to determine whether Cav1 association correlates with Panx1 endocytosis. Here, we observed a significant decrease in colocalization between Panx1 and Cav1 after ATP stimulation ( Figure 1A-1C) , indicating that Panx1 endocytosis occurs independently of a Cav1 association.
Recent studies by Boyce et al 49 and Gehi et al 43 report similar codistributions of Panx1 with Cav1 in cell lines. In contrast to the phenylephrine-induced Panx1/Cav1 clustering observed herein, a similar decrease in overlap with Cav1 was observed after ATP application in N2a cells. 49 It is important to note in this context that Cav1-enriched caveolae are only 1 specialized variety of cholesterol-enriched membrane microdomain or lipid raft. 5 In fact, ATP-mediated Panx1 internalization is cholesterol dependent 49, 50 but dynamin and clathrin independent, 43, 49 suggestive of a noncanonical endocytosis mechanism. Our novel results then suggest that inclusion of Panx1 in VSMC caveolae may alter channel activity (such as increased open probability [56] [57] [58] ) rather than trafficking although this remains to be explicitly tested. In light of this work, and because of the strong association between caveolin-1 and Panx1 after adrenergic stimulation, we tested whether an endogenous interaction occurs in VSMCs. The same culture model also showed a specific protein interaction using immunoprecipitation of membrane fractions after phenylephrine stimulation ( Figure 1D-1F) , which was absent in noncaveolar Panx1-containing fractions. In these experiments, we observed multiple glycosylation species of Panx1 59, 60 (between 37 and 55 kDa) after immunoprecipitation, perhaps indicative of the recruitment of more Panx1 channels from intracellular stores after stimulation. Panx1 channels are oligomers of Panx1 subunits. It is unknown how many units within the channel must be glycosylated to allow for the appropriately trafficking of plasma membrane channels. It is plausible that Panx1 subunits are differentially regulated, which has been strongly suggested in other published work. 29 It also remains unclear whether binding of Panx1 to Cav1 after phenylephrine stimulation requires a direct interaction, which has been observed for other membrane channels, [56] [57] [58] or if other membrane-associated effector molecules are required, such as Src family kinases. 61, 62 Panx1 plays a vital role in α-AR vasoconstriction but not in other constriction pathways. 22 We reasoned that caveolae might engender the formation of α-AR membrane microdomains near the VSMC membrane innervated by sympathetic nerves. Using intact mouse resistance arteries in conjunction with PLA, we observed an adrenergic-induced interaction of Cav1 and Panx1 preferentially localized around sympathetic nerves ( Figure 2D and 2E ). These observations suggest that caveolae may support the formation of a signaling microdomain important for Panx1 activation. 22 Moreover, resistance arteries are characterized by multiunit neural innervation to VSMCs, whereby small patches of VSMCs are contacted by sympathetic nerves to allow for finer individual control of vasoconstriction. 63 This innervation pattern differs from the unitary innervation observed in visceral organs and large arteries, which features a single VSMC neural input and relies on gap junction connectivity to synchronize constriction responses. In this study as in previously published findings, 21 we detect a scarcity of gap junction connectivity between VSMCs in our models by connexin 43 immunostaining herein ( Figure III in the online-only Data Supplement) or electron microscopy. 21 These results suggest that resistance arteries may preferentially use autocrine/paracrine-mediated signals to couple VSMC constriction responses and may further use purinergic signaling pathways mediated through Panx1 to facilitate this function.
The idea that spatially localized signals support vascular function has been extensively characterized in the endothelium, where regulation of tyrosine kinases and endothelial nitric oxide synthase is dependent on Cav1
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; however, less is known about these processes in VSMCs, which use sympathetic innervation to adjust vascular resistance for proper BP control. 64 Perturbations to this adrenergic signaling axis may underlie clinical pathologies in patients experiencing treatment-resistant hypertension who present with enhanced sympathetic drive, norepinephrine spillover, and excessive vascular resistance. [65] [66] [67] To explore the functional role of Cav1 in VSMCs, we generated an inducible VSMC-specific Cav1 knockout mouse ( Figure 3A and 3B) to selectively removed Cav1 from the vascular media ( Figure 3C ). Importantly, Cav1 expression remained present in the vascular endothelium (CD31-positive cells) between control and knockout mice. No gross alterations in the medial wall thickness or cell number were observed in TDAs (data not shown) as was described for pulmonary arteries in the constitutive global knockout. 13 It is likely that the use of an inducible Cre-recombinase system in adult mice curtailed any negative compensatory effects seen in constitutive systems.
Using ATP bioluminescence assays, we measured phenylephrine-stimulated ATP release from ex vivo arteries, a process that our laboratory has shown uniquely couples with Panx1 activation. 22 In all cases, Cav1 deletion significantly reduced phenylephrine-and norepinephrine-stimulated ATP release, similar to observations in Panx1 VSMC-knockout mice 22 ( Figure 3E ). From our immunofluorescence analyses, it seems likely that Panx1 is the primary conduit for ATP release from In the vasculature, a primary role for Cav1 is ascribed to negative regulation of endothelial nitric oxide synthase activity in the endothelium. 68, 69 Global deletion of Cav1 increases endothelial nitric oxide synthase activity, resulting in higher concentrations of cGMP, increased nitric oxide release, and alterations in myogenic tone and dilation responses to acetylcholine. 16, 52 However, the role of VSMC-derived Cav1 has not been specifically examined in resistance arteries. Using pressure myography, we found that VSMC Cav1 deletion significantly blunts phenylephrine-stimulated vasoconstriction responses but does not change vasodilation responses to acetylcholine ( Figure 4A and 4B) , indicating that reduced vasoconstriction is not dependent on endothelial-derived mechanisms observed in global Cav1 knockout models. 13 ATP release from the vascular wall exhibits dual activities in resistance arteries dependeing on which cell type release ATP (vasoconstriction in smooth muscles and vasodilation in endothelial cells). The subtypes of purinergic receptors that are activated by ATP can also influence responses within the vascular wall with the largest contribution in smooth muscle being mediated by P2X1 ionotropic receptors. 70 Our laboratory has demonstrated the existence of purinergic component to adrenergic-mediated vascular events, whereby incubation of vessels with the ATP degrading enzyme apyrase or pharmacological blockers of purinergic receptors (P2X) prevents adrenergic vasoconstriction. 21 Thus, we conclude that Cav1 in our model functionally regulates the initial and upstream release of ATP used to activate downstream purinergic receptors after adrenergic stimulation.
VSMC-specific deletion of Cav1 results in reduced adrenergic ATP release and vasoconstriction, a similar vascular phenotypic observed when Panx1 is specifically deleted from VSMCs. We predicted that a similar dysregulation in BP would then occur after Cav1 deletion as observed in Panx1 knockout models: specifically, a reduction in MAP predominantly during the animal's active period (night MAP), when sympathetic drive is high. Indeed, in vivo BP monitoring revealed a significant reduction in 24-hour MAP ( Figure 5A and 5B) with a greater reduction occurring at night ( Figure 5C ) in Cav1-deficient animals but not during the day (inactive period; Figure 5D ). The effect size of BP lowering because of Cav1 deletion (≈4 mm Hg, 24-hour MAP; ≈6 mm Hg, night MAP) was nearly identical to BP reductions in VSMC-Panx1 knockout animals. 52 To further confirm that alterations in MAP were due to vascular changes (reduced vascular resistance), we assessed cardiac function using MRI. No measurable morphological differences were detected in our analysis, and all animals were functionally similar (eg, heart rate, stroke volume; Table) . Therefore, alterations in vascular resistance because of VSMC Cav1 deletion are likely responsible for observed reductions in MAP.
To determine whether Cav1-dependent BP responses utilize, in part, a Panx1-dependent pathway, we acutely treated animals with Px1IL2P peptide to pharmacologically lower BP. Px1IL2P has previously been shown to significantly Cardiac function is unaltered in vascular smooth muscle cell caveolin-1-deficient mice. Magnetic resonance imaging was performed on a 7 Tesla (T) Clinscan system (Bruker, Ettlingen, Germany) equipped with actively shielded gradients with a full strength of 650 mT/m and a slew rate of 6666 mT/m per millisecond. Baseline left ventricular structure and function were assessed. Six short-axis slices were acquired from base to apex, with slice thickness equal to 1 mm, in-plane spatial resolution of 0.2×0.2° mm 2 , and temporal resolution of 8 to 12 ms. Baseline EF, end-diastolic volume (EDV), end-systolic volume (ESV), myocardial mass, wall thickness, and wall thickening were measured from the cine images using the freely available software Segment version 2.0 R5292 (http://segment.heiberg.se). EDV and ESV were then indexed to body mass. Mass to volume ratio (MVR) was calculated as the ratio of myocardial mass to EDV. A Student t test (2 tailed) was performed for significance; *P<0.05.
Data represented as mean±SEM, n=4, 2-tail homoscedastic Student t test. Cav1 indicates caveolin-1; CO, cardiac output; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LVM, left ventricle mass; R-R, R-R wave ECG interval; SMC, smooth muscle cell; and SV, stroke volume.
reduce adrenergic-stimulated Panx1 channel opening and ATP release, but also shown to potently lower BP in mice. In the current analysis, wild-type and control mice dramatically respond to PxIL2P treatment (ie, reduced BP lowering), with no effects because of scrambled control peptide. 22 However, conditional deletion of VSMC Cav1 are completely protected to BP lowering by Px1IL2P treatment. This strongly suggests that Cav1 is a key intermediary necessary for normal Panx1 function ( Figure 7 ). These data further highlight the Panx1 intracellular loop as an important target for Panx1 activation. Previous work from our group has demonstrated that the region mapping to the Px1IL2P peptide contains a regulatory motif, which on genetic mutation negatively influences Panx1 channel function and adrenergic-mediated vasoconstriction. 22 Future studies are needed to determine whether Cav1 directly influences the Panx1 intracellular loop or whether associative factors bound to Cav1 are required for proper channel function.
In this analysis, we explore a novel adrenergic vasoconstriction pathway that has previously been shown to coordinate constriction responses through the release of ATP by Panx1. We describe the impact of Cav1 deletion in the peripheral vasculature and on systemic BP regulation using a novel smooth muscle-specific mouse model. We have tried to limit compensatory changes resultant from Cav1 deletion by utilizing an inducible Cre-lox system in adult mice. Based on our analyses, we found no additional phenotypes outside of the cardiovascular phenotypes reported in this study. Although, direct experimental evidence and future studies are required to determine whether additional phenotypes exist. Here, we show that the localization of Panx1 to plasma membrane caveolae and the scaffold protein Cav1 promotes a novel interaction important for regulating BP. It remains to be observed whether other scaffold proteins or cytoskeletal proteins contribute to the localization and formation of this unique membrane domain near sympathetic nerve terminals in VSMC. Panx1 has been shown to directly interact with the actin cytoskeleton 71 and its modulator actin-related protein 3, 72, 73 and treatment with cytochalasin B destabilized Panx1 plasma membrane distribution in vitro. 71 It is also unknown which intracellular mediators are mechanistically required for activation of Panx1 by α-AR in VSMCs, which will be especially important to determine.
Overall, our data demonstrate that Panx1 and Cav1 functionally couple with each other in VSMCs. Using immunofluorescence colocalization and coimmunoprecipitation, we show that Cav1 and Panx1 interact at distinct areas of VSMC plasma membrane innervated by sympathetic nerves, suggesting the existence of an adrenergic microsignaling domain. This interaction was induced by α-AR stimulation and is necessary for adrenergic-mediated vasoconstriction and ATP release from resistance arteries. We found that VSMC Cav1 is necessary to control systemic BP responses through modulation of Panx1 function and may facilitate appropriate channel function through the Panx1 intracellular loop region.
Perspectives
A strong medical need exists for an effective, safe, and innovative pharmacological therapy that promotes BP regulation and reduces the vasoconstriction that accompanies excessive sympathetic stimulation. Our observations demonstrating an adrenergic-mediated interaction between VSMC Cav1 with Panx1 and the subsequent caveonlin-1-dependent control of vascular responsiveness and BP homeostasis are important for expanding our knowledge of a novel adrenergic signaling pathway that may underlie treatment-resistant hypertension. In the future, our goal is to elucidate signaling partners involved in forming functional adrenergic signaling microdomains and determine their applicability as targets for therapeutic intervention. , or C57BL/6 mice. Changes in MAP were calculated using each animal's individual baseline pretreatment. n=4 mice for each treatment group; *P<0.05 and **P<0.01 compared with individual baseline response using 2-way ANOVA and Tukey test. n.s. indicates nonsignificance.
